Overview

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Status:
Not yet recruiting

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy. The study planned to enroll 400 subjects in a 1:1 ratio and stratified block randomization method assigned to: - Experimental group: JSKN003 monotherapy - Control group: investigator's chosen chemotherapy drug (capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin) monotherapy

Phase:

Phase 3

Details

Lead Sponsor:

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Treatments:

Capecitabine
Docetaxel
Gemcitabine
Paclitaxel
Vinorelbine